Published online Jun 7, 2017. doi: 10.3748/wjg.v23.i21.3907
Peer-review started: September 18, 2016
First decision: October 10, 2016
Revised: October 27, 2016
Accepted: December 8, 2016
Article in press: December 8, 2016
Published online: June 7, 2017
Processing time: 263 Days and 10.6 Hours
To detect the expression of pleiotrophin (PTN) and N-syndecan in pancreatic cancer and analyze their association with tumor progression and perineural invasion (PNI).
An orthotopic mouse model of pancreatic cancer was created by injecting tumor cells subcapsularly in a root region of the pancreas beneath the spleen. Pancreatic cancer tissues were taken from 36 mice that survived for more than 90 d. PTN and N-syndecan proteins were detected by immunohistochemistry and analyzed for their correlation with pathological features, PNI, and prognosis.
The expression rates of PTN and N-syndecan proteins were 66.7% and 61.1%, respectively, in cancer tissue. PTN and N-syndecan expression was associated with PNI (P = 0.019 and P = 0.032, respectively). High PTN expression was closely associated with large bloody ascites (P = 0.009), liver metastasis (P = 0.035), and decreased survival time (P = 0.022). N-syndecan expression was significantly associated with tumor size (P = 0.025), but not with survival time (P = 0.539).
High PTN and N-syndecan expression was closely associated with metastasis and poor prognosis, suggesting that they may promote tumor progression and PNI in the orthotopic mouse model of pancreatic cancer.
Core tip: Perineural invasion (PNI) is a primary cause of local recurrence and poor survival in patients with pancreatic cancer. However, the exact mechanism of PNI remains unclear. Pleiotrophin (PTN) and its receptor, N-syndecan, may play an important role in tumor growth and PNI of pancreatic cancer. In a previous study, we found that high expression of PTN and N-syndecan may contribute to increased PNI and poor prognosis in patients with pancreatic cancer. In this study, we further elucidated the function of PTN and N-syndecan using an orthotopic mouse model of pancreatic cancer. We demonstrated that PTN and N-syndecan promoted tumor progression and PNI.